Refine by
Tumor Modeling Articles & Analysis
49 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and ...
The first candidate under development by Oncovita, MVdeltaC, is an immunotherapeutic treatment for solid tumors and has demonstrated remarkable immunogenic oncolysis properties in human or syngeneic tumor models, e.g. mesothelioma, bladder, neuroblastoma, etc. ...
ByOncoVITA
The range of PC basic research services includes PC pathology research, PC cell research, PC stem cell research, PC tumor model, and more. At the same time, Alfa Cytology can also offer drug development services for pancreatic cancer with the data obtained from PC basic research. ...
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. ...
ByCELLINK
These results, along with a mathematical model-informed approach have supported the currently ongoing dose expansion for BAY 2416964. ...
ByBayer AG
The results demonstrated over 50% tumor reduction in a murine glioblastoma model. The study was conducted by an independent pre-clinical research organization. ...
Highlights: ES019 phagocytosis activity is corrected with PD-L1 level on tumor cells ES019 leads to better phagocytosis capability of tumor cells by M2-like than M1-like macrophage ES019 activates T cells without induction of phagocytosis of T cells ES019 shows favorable PK in mouse model ES019 demonstrates single agent ...
CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemotherapy agents. ...
About PMC-309 PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, an immune checkpoint receptor mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it can play a pivotal role in maintaining the immunosuppressive ...
To date, IO-108 has been well tolerated with demonstrated clinical activity in multiple tumor types, both as a monotherapy and in combination with pembrolizumab, an anti-PD-1 antibody. ...
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant ...
This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge diagnostic PARIS Test to first responders and other patients at Vincere Cancer Center. A patient’s tumor biopsy or surgical resection will be generated at Vincere and then sent to SEngine’s laboratory in Seattle, where up to 44 drugs from a library of over 240 options ...
“Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. ...
AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational status Study demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitors In vivo studies of an AML murine ...
“The addition of Dan Hayes to our CAB highlights the excitement of building our MOS technology across important tumor types. To have five of the world’s leading oncologists recognize the potential of our MOS technology to revolutionize the way we approach cancer therapy is gratifying,” said David Hsu, MD, co-founder of Xilis. ...
“Our conditionally activated TCB platform is designed to localize both target binding and T-cell activation selectively to the tumor microenvironment, minimizing extra-tumoral activation of T cells and potentially widening the therapeutic window for solid tumor-directed TCBs. ...
Moreover, IO-108 monotherapy inhibits the growth of solid tumors in a preclinical model, which is associated with immune cell activation. IO-108 presents a favorable pharmacokinetic and safety profile in preclinical models. In the ongoing Phase 1 study of IO-108 in adult patients with advanced or refractory solid tumors in the ...
Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer. The study was the result of work by an international consortium, ...
JBI-802 is a first-in-class, orally administered, dual equipotent inhibitor of LSD1 & HDAC6 JBI-802 demonstrated synergistic anti-tumor activity in animal models Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced the ...
Immune-Onc and The University of Texas published pioneering research in Nature illuminating the role of LILRB4 in immune suppression and tumor infiltration in acute myeloid leukemia (AML) and presented the rationale for targeting LILRB4 in solid tumors at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ...